The aim of this study was to perform a systematic review and outcome evaluation of published and ongoing studies of mavacamten therapy for the treatment of hypertrophic cardiomyopathy (HCM). HCM is a common hereditary heart disease with an estimated prevalence of 1 in 200-500 cases and poses a significant threat to young adults and athletes. Sequence differences in numerous genes encoding proteins of thick and thin cardiac myofilaments responsible for cardiac sarcomere contraction are the genetic basis of HCM. Hypertrophic cardiomyopathy is spread in an autosomal dominant manner by pathogenic mutations. Hypertrophic cardiomyopathy is usually divided into obstructive (about 70%) and nonobstructive subtypes. The clinical presentation of HCM ranges from asymptomatic to drug-resistant progressive heart failure. Mavacamten is a leading myosin inhibitor that has made progress in in vitro studies. It has shown promising results in patients with symptomatic hypertrophic obstructive cardiomyopathy. PubMed, EMBASE, Clinicaltrials.gov, and Medline databases were searched by keyword for existing literature on mavacamten for the treatment of HCM. Cross-referencing was used to determine the relevance of retrieved articles and identify biases. A total of 1066 studies were found in the initial keyword search. These articles were subject to eligibility criteria to ensure relevance to the purpose of the review. By stratifying possible publications, nine studies were identified for inclusion in the review, including randomized clinical trials, clinical trials, and ongoing trials. We then performed a meta-analysis of the Mavacamten estimation results using the Cochrane Meta-Analytic Tool and visualized the results as forest plots and explanatory tables. Treatment of symptomatic obstructive cardiomyopathy with mabacamtene had a significant impact on the following key outcomes: B. Improving left ventricular occlusive path slope and increasing peak oxygen consumption and secondary outcomes such as quality of life. Myosin inhibitors are a potential short-term and potential alternative therapeutic intervention for patients with symptomatic HOCM, as suggested by the significant benefits such as improved quality of life and increased lifespan associated with mavacamten therapy for HCM patients. May be used long term.
Author(s) Details:
Ziad Affas,
Department of Internal Medicine, Henry Ford Macomb Hospital, Michigan, USA.
Ghaid Touza,
Department of Internal Medicine, Henry Ford Macomb Hospital, Michigan, USA.
Rowaid Touza,
Department of Internal Medicine, Henry Ford Macomb Hospital, Michigan, USA.
Saif Affas,
Department of Internal Medicine, Henry Ford Macomb Hospital, Michigan, USA.
Zain Azzo,
Department of Internal Medicine, Henry Ford Macomb Hospital, Michigan, USA.
Ali Shakir,
Department of Internal Medicine, Henry Ford Macomb Hospital, Michigan, USA.
Please see the link here: https://stm.bookpi.org/CIMMS-V2/article/view/8224
No comments:
Post a Comment